Seven patients with active acromegaly were treated with SMS 201-995, an analogue of somatostatin, for one year, the maximum dose being 100 micrograms three times a day. Three patients had impaired glucose tolerance before treatment, due to insulin resistance in two and insulin deficiency in one. In all patients treatment with the analogue slightly increased postprandial glucose concentrations and suppressed insulin concentrations for two to two and a half hours after each injection; growth hormone concentrations decreased progressively with treatment. The patient with impaired glucose tolerance due to insulin deficiency developed diabetes mellitus after four months' treatment; concomitant treatment with glibenclamide resulted in a decreased glucose concentration and increased insulin concentration. This analogue of somatostatin had only minor side effects on glucose tolerance in patients with acromegaly and may be used in patients with impaired glucose tolerance provided that glucose concentrations are monitored closely.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1342048 | PMC |
| http://dx.doi.org/10.1136/bmj.293.6558.1327 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Social isolation increases impulsive choice with minor changes on metabolic function in middle-aged rats.
Physiol Rep
January 2025
Department of Psychology, University of Illinois Urbana-Champaign, Champaign, Illinois, USA.
The effects of social isolation (SI) during middle age remain unclear, so we tested the hypothesis that SI would lead to an increase in impulsive choice (IC), anxiety-like behavior, and metabolic dysfunction in middle-aged rats. Male and female rats were housed individually or in groups of four with same-sex housing mates at 11 months of age. Two months later, IC behavior was assessed using a delay-discounting task and anxiety-like behavior through a novelty-suppressed feeding (NSF) task.
View Article and Find Full Text PDFImproving detection of monogenic diabetes through reanalysis of GCK variants of uncertain significance.
Acta Diabetol
January 2025
Adelaide Medical School, University of Adelaide, Adelaide, Australia.
Aims: To assess the utility of reanalysing GCK variants of uncertain significance (VUS) as an intervention to improve the detection of monogenic diabetes.
Methods: We examined GCK VUS in a local cohort of individuals with suspected monogenic diabetes and re-curated each variant against the recent ClinGen GCK-specific variant classification guidelines.
Results: Variant reanalysis achieved a new 'likely pathogenic' classification (i.
Untreated women with first trimester fasting glycaemia 92-125 mg/dL and risk of gestational diabetes mellitus in the 24-28th week OGTT: prevalence and predictors.
Acta Diabetol
January 2025
Endocrinology Department, Unidade Local de Saúde Tâmega e Sousa, Penafiel, Portugal.
Introduction: Women with first trimester fasting glycaemia (FTFG) 92-125 mg/dL may present with normal 24-28th week OGTT (2T-OGTT). Predictors of persistent hyperglycaemia were scarcely investigated. We studied the prevalence and predictors of gestational diabetes mellitus (GDM) in the 2T-OGTT in women with untreated elevated FTFG.
View Article and Find Full Text PDFEffectiveness and Safety of Vildagliptin Sustained Release in the Management of Type 2 Diabetes Mellitus: Real-World Evidence in Indian Patients [NOVELTY Study].
Drugs Real World Outcomes
January 2025
Department of Medical Affairs, Cipla Ltd., Mumbai Central, Mumbai, Maharashtra, 400008, India.
Background And Objective: Vildagliptin sustained release (XR), a formulation that provides vildagliptin 100 mg with a once-daily dose administration, is a recent introduction to manage type 2 diabetes mellitus in India. This study aimed to evaluate the effectiveness and tolerability of vildagliptin XR in patients with type 2 diabetes in real-world clinical settings.
Methods: This was an observational, prospective, multicenter, cohort study conducted in India, which included patients with type 2 diabetes uncontrolled on metformin XR monotherapy with glycated hemoglobin (HbA1c) > 7.
Hawthorn carbon dots: a novel therapeutic agent for modulating body weight and hepatic lipid profiles in high-fat diet-fed mice.
Nanoscale
January 2025
Tang Center of Herbal Medicine Research and Department of Anesthesia & Critical Care, University of Chicago, Chicago, IL, 60637, USA.
Obesity, a chronic metabolic disorder characterized by excessive body weight and adipose tissue accumulation, is intricately linked to a spectrum of health complications. It is driven by a confluence of factors, including gut microbiota dysbiosis, inflammation, and oxidative stress, which are pivotal in its pathogenesis. A multifaceted therapeutic strategy that targets these interrelated pathways is essential for effective obesity management.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!